HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma
Our results revealed a novel mechanism by which the HDACi SAHA potentiates CD8+T-cell-mediated antitumor activity through the HDAC1/JAK1/FGL1 axis, providing a rationale for the combined use of HDACis and immunotherapy.
Authors
- Yunru Gu (ORCID: https://orcid.org/0000-0001-5860-5588)
- Haoyang Shen
- Yu Tao (ORCID: https://orcid.org/0000-0001-5087-7474)
- Tong Hu
- Tingting Xu (ORCID: https://orcid.org/0000-0002-5701-9859)
- Yongqian Shu (ORCID: https://orcid.org/0000-0003-2103-0877)
- Pei Ma
- XU Duo
- Yuan Fang (ORCID: https://orcid.org/0000-0002-0245-9291)
- Yang-Yue Xu
Institutions
- Suzhou Municipal Hospital (CN)
- Jiangsu Province Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/jitc-2024-010077
- Citations
- 31
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 7.25
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Nanjing Medical University